{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:27:40Z","timestamp":1781612860140,"version":"3.54.5"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Oesophageal squamous cell carcinoma is a common malignancy worldwide. Definitive chemoradiotherapy is the standard treatment for patients with resectable stage oesophageal squamous cell carcinoma who cannot undergo surgery, as well as those with locally advanced unresectable oesophageal squamous cell carcinoma. However, it has several disadvantages such as poor survival, radiation-related toxicities and severe and lethal complications related to salvage treatment for residual or recurrent disease. Numerous clinical trials on chemoradiotherapy have been conducted to confirm the optimal combination of irradiation and chemotherapy. For advanced disease, multimodal treatment strategies including salvage surgery are essential. Palliative chemoradiotherapy is also crucial for dysphagia in locally advanced oesophageal squamous cell carcinoma with or without metastatic lesions. Recently, the synergistic mechanism of radiotherapy combined with immunotherapy has been reported. Early phase clinical trials suggest that a combination of immunotherapy and chemoradiotherapy can improve clinical outcomes with manageable side effects, but further investigations are needed. Here, we reviewed the existing clinical data and current development of chemoradiotherapy combined with immunotherapy in patients with oesophageal squamous cell carcinoma.<\/jats:p>","DOI":"10.1093\/jjco\/hyae005","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T02:20:00Z","timestamp":1707704400000},"page":"395-402","source":"Crossref","is-referenced-by-count":11,"title":["Recent progress in chemoradiotherapy for oesophageal squamous cell carcinoma"],"prefix":"10.1093","volume":"54","author":[{"given":"Kotoe","family":"Oshima","sequence":"first","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3551-7504","authenticated-orcid":false,"given":"Takahiro","family":"Tsushima","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Showa University School of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-5072","authenticated-orcid":false,"given":"Ken","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"key":"2024040806013423100_ref1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020","volume":"163","author":"Morgan","year":"2022","journal-title":"Gastroenterology"},{"key":"2024040806013423100_ref2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1053\/j.gastro.2017.09.048","article-title":"Management of patients with adenocarcinoma or squamous cancer of the esophagus","volume":"154","author":"Ilson","year":"2018","journal-title":"Gastroenterology"},{"key":"2024040806013423100_ref3","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s12328-020-01237-x","article-title":"Epidemiology of esophageal cancer: update in global trends, etiology and risk factors","volume":"13","author":"Uhlenhopp","year":"2020","journal-title":"Clin J Gastroenterol"},{"key":"2024040806013423100_ref4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/1759-7714.13311","article-title":"Trends in the incidence and survival of patients with esophageal cancer: a SEER database analysis","volume":"11","author":"He","year":"2020","journal-title":"Thorac Cancer"},{"key":"2024040806013423100_ref5","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","article-title":"Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus","volume":"326","author":"Herskovic","year":"1992","journal-title":"N Engl J Med"},{"key":"2024040806013423100_ref6","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1200\/JCO.2003.03.055","article-title":"Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus","volume":"21","author":"Ishikura","year":"2003","journal-title":"J Clin Oncol"},{"key":"2024040806013423100_ref7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jtcvs.2008.05.016","article-title":"Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma","volume":"137","author":"Tachimori","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2024040806013423100_ref8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00268-009-0331-9","article-title":"Factors influencing the long-term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy","volume":"34","author":"Takeuchi","year":"2010","journal-title":"World J Surg"},{"key":"2024040806013423100_ref9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jjco\/hyw082","article-title":"Chemoradiotherapy for esophageal squamous cell cancer","volume":"46","author":"Sasaki","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"2024040806013423100_ref10","volume-title":"Japanese classification of Esophageal cancer","author":"Japan Esophageal Society","year":"2022","edition":"12th"},{"key":"2024040806013423100_ref11","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/jjco\/hyp069","article-title":"A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan clinical oncology group study (JCOG9708)","volume":"39","author":"Kato","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"2024040806013423100_ref12","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1053\/j.gastro.2021.08.007","article-title":"Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma","volume":"161","author":"Kato","year":"2021","journal-title":"Gastroenterology"},{"key":"2024040806013423100_ref13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jjco\/hyad137","article-title":"A phase III randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer: armadillo trial (JCOG1904)","volume":"54","author":"Sasaki","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"2024040806013423100_ref14","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1010-7940(01)01003-X","article-title":"Clinicopathologic characteristics and survival of patients with clinical stage I squamous cell carcinomas of the thoracic esophagus treated with three-field lymph node dissection","volume":"20","author":"Igaki","year":"2001","journal-title":"Eur J Cardiothorac Surg"},{"key":"2024040806013423100_ref15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/modpathol.3800557","article-title":"Histopathological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: analysis of august 2019 diagnostic ER plus selective CRT for clinical stage I ESCC 389 clinical at 464 surgically resected cases","volume":"19","author":"Eguchi","year":"2006","journal-title":"Mod Pathol"},{"key":"2024040806013423100_ref16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1440-1746.2007.05259.x","article-title":"Risk factors of lymph node metastasis in T1 esophageal squamous cell carcinoma","volume":"23","author":"Kim","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"2024040806013423100_ref17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1440-1827.2008.02224.x","article-title":"Lymphatic invasion according to D2-40 immunostaining is a strong predictor of nodal metastasis in superficial squamous cell carcinoma of the esophagus: algorithm for risk of nodal metastasis based on lymphatic invasion","volume":"58","author":"Tomita","year":"2008","journal-title":"Pathol Int"},{"key":"2024040806013423100_ref18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1053\/j.gastro.2019.04.017","article-title":"Efficacy of endoscopic resection and selective chemoradiotherapy for stage I esophageal squamous cell carcinoma","volume":"157","author":"Minashi","year":"2019","journal-title":"Gastroenterology"},{"key":"2024040806013423100_ref19","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ijrobp.2010.06.033","article-title":"Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II\u2013III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906)","volume":"81","author":"Kato","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024040806013423100_ref20","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1200\/JCO.2014.59.9092","article-title":"Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option?","volume":"33","author":"Markar","year":"2015","journal-title":"J Clin Oncol"},{"key":"2024040806013423100_ref21","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann Oncol"},{"issue":"20","key":"2024040806013423100_ref22","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","article-title":"Int 0123 (radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy","volume":"20","author":"Minsky","year":"2002","journal-title":"J Clin Oncol"},{"key":"2024040806013423100_ref23","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ijrobp.2022.07.007","article-title":"A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical stage II\/III esophageal squamous cell carcinoma (JCOG0909 study)","volume":"114","author":"Takeuchi","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024040806013423100_ref24","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","article-title":"Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study)","volume":"39","author":"Hulshof","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024040806013423100_ref25","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.ijrobp.2021.07.045","article-title":"Exclusive chemoradiotherapy with or without radiation dose escalation in esophageal cancer: multicenter phase 2\/3 randomized trial Concorde (PRODIGE-26)","volume":"111","author":"Crehange","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024040806013423100_ref26","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1158\/1078-0432.CCR-21-3843","article-title":"A phase III multicenter randomized clinical trial of 60 Gy versus 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma","volume":"28","author":"Xu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2024040806013423100_ref27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ijrobp.2022.11.006","article-title":"High-dose versus standard-dose IntensityModulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: a randomized, multicenter, open label, phase 3 superiority trial","volume":"115","author":"You","year":"2023","journal-title":"Int J RIAT Oncol Biol Phys"},{"key":"2024040806013423100_ref28","doi-asserted-by":"crossref","first-page":"1034656","DOI":"10.3389\/fonc.2022.1034656","article-title":"The role of involved field irradiation versus elective nodal irradiation in definitive radiotherapy or chemoradiotherapy for esophageal cancer \u2013 a systematic review and meta-analysis","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"2024040806013423100_ref29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","article-title":"Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial","volume":"15","author":"Conroy","year":"2014","journal-title":"Lancet Oncol"},{"key":"2024040806013423100_ref30","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"2024040806013423100_ref31","first-page":"e12574","article-title":"Cisplatin\/5-fluorouracil (5-FU) versus carboplatin\/paclitaxel chemoradiotherapy as definitive or pre-operative treatment of esophageal cancer","volume":"13","author":"Steber","year":"2021","journal-title":"Cureus"},{"key":"2024040806013423100_ref32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dox015","article-title":"Neoadjuvant chemoradiotherapy with concurrent cisplatin\/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin\/paclitaxel in patients with locally advanced esophageal cancer","volume":"30","author":"Haisley","year":"2017","journal-title":"Dis Esophagus"},{"key":"2024040806013423100_ref33","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.3390\/cancers14112610","article-title":"Neoadjuvant carboplatin\/paclitaxel versus 5-fluorouracil\/cisplatin in combination with radiotherapy for locally advanced esophageal squamous cell carcinoma: a multicenter comparative study","volume":"14","author":"Gao","year":"2022","journal-title":"Cancer"},{"key":"2024040806013423100_ref34","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.21873\/invivo.12638","article-title":"Paclitaxel and carboplatin versus cisplatin and 5-fluorouracil in concurrent chemoradiotherapy in patients with esophageal cancer","volume":"35","author":"Su","year":"2021","journal-title":"In Vivo"},{"key":"2024040806013423100_ref35","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/cas.12764","article-title":"Phase I\/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II\/III esophageal carcinoma (JCOG 0604)","volume":"106","author":"Tahara","year":"2015","journal-title":"Cancer Sci"},{"key":"2024040806013423100_ref36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/cas.12622","article-title":"Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303)","volume":"106","author":"Shinoda","year":"2015","journal-title":"Cancer Sci"},{"key":"2024040806013423100_ref37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00280-016-3062-2","article-title":"A prospective, multicenter phase I\/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma","volume":"78","author":"Satake","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024040806013423100_ref38","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2005.04.7118","article-title":"Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102","volume":"25","author":"Bedenne","year":"2007","journal-title":"J Clin Oncol"},{"key":"2024040806013423100_ref39","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2005.00.034","article-title":"Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus","volume":"23","author":"Stahl","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024040806013423100_ref40","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/bjc.2016.350","article-title":"Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer","volume":"115","author":"Yokota","year":"2016","journal-title":"Br J Cancer"},{"key":"2024040806013423100_ref41","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/jjco\/hyz112","article-title":"Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE)","volume":"49","author":"Terada","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"2024040806013423100_ref42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","article-title":"A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)","volume":"19","author":"Ando","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"2024040806013423100_ref43","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/jjco\/hyt061","article-title":"Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study)","volume":"43","author":"Nakamura","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"2024040806013423100_ref44","article-title":"Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial","volume":"32","author":"D\u00f6beln","year":"2019","journal-title":"Dis Esophagus"},{"key":"2024040806013423100_ref45","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/jamasurg.2021.0133","article-title":"Morbidity and mortality of patients who underwent minimally invasive Esophagectomy after Neoadjuvant Chemoradiotherapy vs Neoadjuvant chemotherapy for locally advanced Esophageal squamous cell carcinoma: a randomized clinical trial","volume":"156","author":"Wang","year":"2021","journal-title":"JAMA Surg"},{"key":"2024040806013423100_ref46","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/JCO.2022.40.4_suppl.238","article-title":"A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study","volume":"40","author":"Kato","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024040806013423100_ref47","doi-asserted-by":"crossref","first-page":"S1317","DOI":"10.1016\/j.annonc.2023.10.076","article-title":"LBA75 neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial","volume":"34","author":"Van der Wilk","year":"2023","journal-title":"Ann Oncol"},{"key":"2024040806013423100_ref48","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/JCO.2021.39.15_suppl.4027","article-title":"A phase II study of chemoselection with docetaxel, cisplatin, and 5\u2013fluorouracil as a strategy for organ preservation in patients with resectable esophageal cancer (CROC trial)","volume":"39","author":"Katada","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024040806013423100_ref49","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2354.2003.00376.x","article-title":"The experience of dysphagia and its effect on the quality of life of patients with oesophageal cancer","volume":"12","author":"Watt E, Whyte F. Research","year":"2003","journal-title":"Eur J Cancer Care"},{"key":"2024040806013423100_ref50","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","article-title":"Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1","volume":"20","author":"Kitagawa","year":"2023","journal-title":"Esophagus"},{"key":"2024040806013423100_ref51","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s10147-018-1324-1","article-title":"Palliative radiotherapy and chemoradiotherapy in stage IVA\/B esophageal cancer patients with dysphagia","volume":"23","author":"Kawamoto","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"2024040806013423100_ref52","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.3390\/curroncol30070447","article-title":"Endoscopic stenting for malignant dysphagia in patients with esophageal cancer","volume":"30","author":"Ishihara","year":"2023","journal-title":"Curr Oncol"},{"key":"2024040806013423100_ref53","doi-asserted-by":"crossref","first-page":"569","DOI":"10.6004\/jnccn.2019.7524","article-title":"Palliative radiotherapy versus esophageal stent placement in the management of patients with metastatic esophageal cancer","volume":"18","author":"Martin","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2024040806013423100_ref54","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S2468-1253(17)30363-1","article-title":"Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01)","volume":"3","author":"Penniment","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024040806013423100_ref55","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2217\/fon-2020-0545","article-title":"Immuno-oncology for esophageal cancer","volume":"16","author":"Yamamoto","year":"2020","journal-title":"Future Oncol"},{"key":"2024040806013423100_ref56","first-page":"1064","article-title":"Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges","volume":"22","author":"Hodge","year":"2008","journal-title":"Oncology (Williston Park)"},{"key":"2024040806013423100_ref57","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"2024040806013423100_ref58","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/JCO.2019.37.15_suppl.4027","article-title":"A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC)","volume":"37","author":"Hong","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024040806013423100_ref59","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2021","journal-title":"Eur J Cancer"},{"key":"2024040806013423100_ref60","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2021.39.15_suppl.4005","article-title":"Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC)","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024040806013423100_ref61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/JCO.2022.40.4_suppl.321","article-title":"Multicenter phase II study of neoadjuvant nivolumab or nivolumab plus relatlimab (anti-LAG3 antibody) plus chemoradiotherapy in stage II\/III esophageal\/gastroesophageal junction (E\/GEJ) carcinoma","volume":"40","author":"Kelly","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024040806013423100_ref62","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1200\/JCO.2022.40.16_suppl.4034","article-title":"Phase I\/II trial of perioperative avelumab in combination with chemoradiation (CRT) in the treatment of stage II\/III resectable esophageal and gastroesophageal junction (E\/GEJ) cancer","volume":"40","author":"Uboha","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024040806013423100_ref63","article-title":"Neoadjuvant chemoradiotherapy combined with perioperative toripalimab in locally advanced esophageal cancer","volume":"40","author":"Xu","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024040806013423100_ref64","doi-asserted-by":"crossref","first-page":"e1110","DOI":"10.1002\/onco.13797","article-title":"Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma","volume":"26","author":"Zhang","year":"2021","journal-title":"Oncologist"},{"key":"2024040806013423100_ref65","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/cncr.34176","article-title":"Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma","volume":"128","author":"Park","year":"2022","journal-title":"Cancer"},{"key":"2024040806013423100_ref66","doi-asserted-by":"crossref","first-page":"S1102","DOI":"10.1016\/j.annonc.2022.07.1329","article-title":"A multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802)","volume":"33","author":"Bando","year":"2022","journal-title":"Ann Oncol"},{"key":"2024040806013423100_ref67","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(23)00060-8","article-title":"Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial","volume":"24","author":"Zhu","year":"2023","journal-title":"Lancet Oncol"},{"key":"2024040806013423100_ref68","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2217\/fon-2020-0969","article-title":"KEYNOTE-975 study design: a phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma","volume":"17","author":"Shah","year":"2021","journal-title":"Future Oncol"},{"key":"2024040806013423100_ref69","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.2217\/fon-2021-0632","article-title":"RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma","volume":"17","author":"Yu","year":"2021","journal-title":"Future Oncol"},{"key":"2024040806013423100_ref70","doi-asserted-by":"crossref","first-page":"TPS373","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS373","article-title":"A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024040806013423100_ref71","doi-asserted-by":"crossref","first-page":"TPS374","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS374","article-title":"SKYSCRAPER-07: a phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy","volume":"40","author":"Goodman","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/4\/395\/57174448\/hyae005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/4\/395\/57174448\/hyae005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T06:02:34Z","timestamp":1712556154000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/4\/395\/7606132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,10]]},"references-count":71,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2,10]]},"published-print":{"date-parts":[[2024,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae005","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,2,10]]}}}